Presentation is loading. Please wait.

Presentation is loading. Please wait.

Increased IgE levels are linked to faster relapse in patients with omalizumab- discontinued chronic spontaneous urticaria  Ragip Ertas, MD, Kemal Ozyurt,

Published byDeddy Darmali Modified over 6 years ago

Similar presentations

Presentation on theme: "Increased IgE levels are linked to faster relapse in patients with omalizumab- discontinued chronic spontaneous urticaria  Ragip Ertas, MD, Kemal Ozyurt,"— Presentation transcript:

1 Increased IgE levels are linked to faster relapse in patients with omalizumab- discontinued chronic spontaneous urticaria  Ragip Ertas, MD, Kemal Ozyurt, MD, Emin Ozlu, MD, Yilmaz Ulas, MD, Atil Avci, MD, Mustafa Atasoy, MD, Tomasz Hawro, MD, Marcus Maurer, MD  Journal of Allergy and Clinical Immunology  Volume 140, Issue 6, Pages (December 2017) DOI: /j.jaci Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Relapse time in patients with normal (<100 IU/mL) and increased (>100 IU/mL) IgE levels (Kaplan-Meier plot). Time to relapse after discontinuation of omalizumab was shorter in CRs with increased baseline total IgE levels compared with patients with normal IgE levels (log-rank test: χ2 = 5.78, P = .016, n = 26). Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Increased IgE levels are linked to faster relapse in patients with omalizumab- discontinued chronic spontaneous urticaria  Ragip Ertas, MD, Kemal Ozyurt,"

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.
D-dimer: A biomarker for antihistamine-resistant chronic urticaria

D-dimer: A biomarker for antihistamine-resistant chronic urticaria
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
The natural history of soy allergy

The natural history of soy allergy
Allergen immunotherapy: A practice parameter third update

Allergen immunotherapy: A practice parameter third update
Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials  Zuo-Tao Zhao, MD, PhD, Chun-Mei Ji, M Pharm,

Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials  Zuo-Tao Zhao, MD, PhD, Chun-Mei Ji, M Pharm,
Responsiveness and minimal important difference of the urticaria control test  Tatevik Ohanyan, MD, Nicole Schoepke, MD, Bediha Bolukbasi, MD, Martin Metz,

Responsiveness and minimal important difference of the urticaria control test  Tatevik Ohanyan, MD, Nicole Schoepke, MD, Bediha Bolukbasi, MD, Martin Metz,
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome  Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,

Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome  Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial  Marko Kalliomäki, MD, PhD,

Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial  Marko Kalliomäki, MD, PhD,
Desensitization to Chemotherapeutic Agents

Desensitization to Chemotherapeutic Agents
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Pavel Kolkhir, MD, Martin K

Pavel Kolkhir, MD, Martin K
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy  Allen Kaplan, MD, Dennis Ledford,

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy  Allen Kaplan, MD, Dennis Ledford,
An Infant with Atopic Dermatitis and Itching After Ingestion of Milk

An Infant with Atopic Dermatitis and Itching After Ingestion of Milk
Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial  Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.

Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial  Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.
Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J
Allergy testing in predicting outcome of open food challenge to peanut

Allergy testing in predicting outcome of open food challenge to peanut

Similar presentations

Ads by Google